FDA clearance is taking longer: How smart medtech startups are adapting

FDA timelines are getting longer. That  changes how medtech startups should build. 

For medtech founders, FDA clearance has always mattered. But the latest reporting on device review timelines reinforces something we are feeling across the industry: getting to market is taking longer, even as approvals continue to rise. That matters because regulatory timing is no longer just a compliance issue — it is a business issue, a fundraising issue and ultimately a strategy issue. 

As founders, we cannot afford to think of FDA as a separate workstream that happens after the “real” product work is done. The companies that move fastest over time are usually the ones that start with the end in mind: the regulatory pathway, the evidence plan, the quality infrastructure and the commercial story all need to be built together. 

Regulatory is part of the product strategy 

One of the biggest mistakes early-stage medtech teams make is assuming regulatory work is something to optimize later. In reality, your pathway influences almost every major decision you make, from device design to labeling to clinical evidence to launch planning. 

That means the best founders are not asking, “How do we get through FDA as quickly as possible?” They are asking, “How do we build a company that can survive a longer review cycle without losing momentum?” That mindset shift changes everything — especially how you prioritize evidence generation, quality system readiness and investor communication. 

Build for fewer surprises 

Longer approval timelines punish ambiguity. If your claims are unclear, your evidence story is incomplete, or your quality documentation is inconsistent, delays can compound quickly. The strongest startups reduce risk early by pressure-testing their strategy before submission rather than assuming issues can be fixed in the final round. 

That is especially important in connected and software-enabled devices, where cybersecurity expectations are now an explicit part of premarket thinking. For founders, this means cybersecurity cannot be a late-stage add-on. It has to be part of design input, development planning and submission strategy from the beginning. 

Capital planning has to catch up 

Longer timelines also change the financing conversation. If FDA review takes longer, then the gap between milestone funding and commercial revenue gets wider, which means companies need more disciplined runway planning. 

Founders should be honest with investors about what the timeline really looks like and build financing around realistic regulatory scenarios, not optimistic ones. That does not make the story weaker. It usually makes it more credible. 

 In today’s environment, my advice to founders is straightforward: raise more capital than your scenario planning says you need. The runway should be longer than the plan assumes. Regulatory, clinical, reimbursement, and commercialization milestones, even though sequenced properly, are often uncertain, taking longer than founders expect,” said Kevin Kelley, Avio’s Managing Director and part of our Navigator Network, a curated group of C-Suite leaders who serve as strategic co-pilots. “A solid investment partner recognizes this. They don’t penalize the delay; they appreciate realistic milestones for what they are: the mechanism that de-risks the company.    

Use the review period well 

A longer FDA review does not have to mean a passive one. Smart startups use that time to deepen relationships with clinicians, sharpen the launch narrative and prepare the market for adoption. They also build the commercial assets that will matter once clearance arrives: reimbursement support, training materials, early adopter strategy and channel readiness. 

“At Agitated Solutions, launch planning starts 12-18 months before we anticipate clearance,” says Liz Groover, Director of Market Development for ASI and a member of Avio’s Navigator Network. “We use that time to build awareness around the problem through publications and educational programming, engaging KOLs along the way to amplify the conversation. At the same time we are creating our product branding and messaging, reimbursement narrative, commercialization plan and sales and training tools in preparation for launch. By the time we have the green light to commercialize, we will have already created market need, built a brand presence and generated a sales pipeline.” 

In many cases, the difference between a cleared device and a successful device is not the decision letter. It is whether the team used the regulatory window to build real market pull. 

What strong founders do differently 

The most effective medtech founders are building companies that are ready for delay without being defined by it. They align regulatory, quality, clinical and commercial planning early and they treat each of those as part of the same growth engine. 

That is the real lesson in today’s environment. Approval speed matters, but preparedness matters more. The startups that win will be the ones that can stay disciplined through a longer process and still emerge with a product, a story and a launch plan that are all ready at the same time. 

At Avio Medtech, we help you champion, accelerate and navigate your unique path to market. If you are planning for a regulatory submission and want to get real about what to expect, reach out. If you’ve already submitted, we’d love to hear from you about how you are optimizing the runway now for future growth. And, if you’re not sure; we can help you plot a course.  

FAQ 

How long should we plan for a 510(k), De Novo or PMA to be reviewed by the FDA? 
For a 510(k), most startups should plan for about 6 months, with the understanding that some submissions move faster and others take longer if FDA issues questions or additional information requests. A De Novo may take up to a year to receive clearance and for a PMA, the planning assumption should be much longer — often 24 months or more, depending on the complexity of the device and the evidence package. The most important thing is not to build around the fastest possible path. Build around a realistic timeline that includes review back-and-forth, internal response time, and enough runway to keep the company moving while the submission is under review. 

How should a startup think about longer FDA review timelines? 
Longer timelines should be treated as a planning reality, not a surprise. The best startups build their regulatory, clinical and commercial strategy around a realistic timeline from day one, rather than assuming review will move quickly. 

What can we do early to reduce the risk of delays? 
Start early on pathway selection, intended use, claims and evidence planning. The more clearly you define the product and its supporting data before submission, the less likely you are to run into avoidable back-and-forth later. 

How can an experienced regulatory partner help shorten timelines? 
An experienced regulatory partner can help shorten timelines by identifying issues early, choosing the right pathway, and building a stronger submission from the start. That reduces avoidable back-and-forth with FDA, limits rework, and helps the company stay aligned on evidence, quality, and claims throughout development. 

How does a longer review cycle affect fundraising? 
It usually means you need more runway than you first thought. Investors are generally more comfortable when a company shows it understands the timeline and has built a funding plan that can carry the business through regulatory review and beyond. 

What should startups do during the FDA review period? 
Use that time to build market readiness. That includes developing reimbursement strategy, clinical education materials, key opinion leader relationships, launch planning and internal processes so you are ready to move once clearance comes through. 

Why does quality matter so much in this environment? 
Because quality is no longer just an internal compliance function — it is a signal of company maturity. A strong quality system shows regulators, investors and partners that the startup is prepared to scale responsibly and can handle the scrutiny that comes with bringing a medical device to market.